The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof:

##STR00001##

wherein Q is selected from O, S and Se; J is S or Se; W.sup.1 and W.sup.2, when present, are independently selected from N and C; R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W.sup.1 and W.sup.2 is present and is a nitrogen atom and when R.sup.1 or R.sup.2 are cyclic then the respective W.sup.1 or W.sup.2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

Described herein are methods for using compounds that activate pyruvate kinase.

Described herein are methods for using compounds that activate pyruvate kinase.

Described herein are methods for using compounds that activate pyruvate kinase.

Described herein are methods for using compounds that activate pyruvate kinase.

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI): ##STR00001##
wherein Y is C.sub.1-C.sub.12 alkylene or C.sub.1-C.sub.12 alkenylene; and R.sup.8 and R.sup.12 are independently C.sub.1-C.sub.12 alkyl.

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI): ##STR00001##
wherein Y is C.sub.1-C.sub.12 alkylene or C.sub.1-C.sub.12 alkenylene; and R.sup.8 and R.sup.12 are independently C.sub.1-C.sub.12 alkyl.

Provided is a compound of Formula (I):

##STR00001## wherein the variable groups are defined herein.

The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: ##STR00001##
wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently CR.sub.2? or N?, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, S(?O).sub.2NHR.sub.8, R.sub.8 is, for example, a C.sub.1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates. ##STR00001##